Program Schedule

264
Results of the Surveillance of Tedizolid Activity and Resistance (STAR) Program: In Vitro Susceptibility of Gram-Positive Clinical Isolates Collected in 2013 From the United States

Session: Poster Abstract Session: Antimicrobial Resistance: Novel Agents and Approaches to Gram-positive Infections
Thursday, October 9, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC

Background: Tedizolid is a novel oxazolidinone antibacterial with potent activity against a wide range of Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), a key pathogen associated with acute bacterial skin and skin structure infections (ABSSSI). As part of the Surveillance of Tedizolid Activity and Resistance (STAR) Program, the in vitro activity of tedizolid was analyzed against a variety of clinically relevant Gram-positive pathogens isolated from clinical sources in 2013.

Methods: Nonduplicate, nonconsecutive, single-patient clinical isolates of key Gram-positive pathogens (N = 1473) were collected from 36 clinical centers in the United States in 2013. Isolates underwent susceptibility testing against tedizolid in accordance with CLSI M7 and M100 guidelines at a central laboratory (Eurofins, Chantilly, VA).

Results: Tedizolid MIC values were determined for S. aureus (n = 1088), CoNS (n = 110), and enterococci (n = 275) from various infection/lesion sites. Tedizolid was active against all of these pathogen groups, with MIC90 values of 0.5 g/mL for MRSA and MSSA; 0.25 g/mL for CoNS; and 0.5 g/mL for enterococci.

 

Pathogen

Isolates (n)

Tedizolid MIC (g/mL)

 

 

Range

Mode

MIC50

MIC90

All S. aureus

1088

≤0.03-1.0

0.25

0.25

0.5

MRSA

499

≤0.03-1.0

0.25

0.25

0.5

MSSA

589

≤0.03-1.0

0.25

0.25

0.5

CoNS

110

≤0.03-0.5

0.12

0.12

0.25

Enterococcus spp

275

0.06-2.0

0.25

0.25

0.5

MIC50 = 50% minimum inhibitory concentration; MIC90 = 90% minimum inhibitory
concentration

 

Conclusion: Based on MIC90 values, tedizolid retains potent activity against Gram-positive pathogens implicated in ABSSSI, including MRSA. The results obtained in this analysis are consistent with the findings obtained in tedizolid surveillance studies conducted in prior years. The serious public health problem of antibacterial resistance warrants continued surveillance of tedizolid activity.

 

Paul Bien and Philippe Prokocimer, Cubist, San Diego, CA

Disclosures:

P. Bien, Cubist: Employee, Salary

P. Prokocimer, Cubist: Employee and Shareholder, Salary

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, idweek.org. All Rights Reserved.

Follow IDWeek